期刊
ANNALS OF ONCOLOGY
卷 29, 期 3, 页码 563-572出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdy003
关键词
APOBEC; immune escape; drug resistance; human immunodeficiency virus; intratumour heterogeneity
类别
资金
- Cancer Research UK
- Rosetrees
- University College London Hospitals Biomedical Research Centre
- Danish Cancer Society
- Swedish Research Council
- NovoNordisk Foundation [16584]
- Danish National Research Foundation (project CARD)
- Danish Council for Independent Research
- USAID
- National Institutes of Health [NIAID R37 AI064046, NCI R21 CA206309]
- Rosetrees Trust
- EU [259303]
- Prostate Cancer Foundation
- Breast Cancer Research Foundation
- European Research Council
- National Institute for Health Research University College London Hospitals Biomedical Research Centre
- Francis Crick Institute from Cancer Research UK [FC001169]
- UK Medical Research Council [FC001169]
- Wellcome Trust [FC001169]
- Cancer Research UK [22246, 24956] Funding Source: researchfish
- The Danish Cancer Society [R124-A7785] Funding Source: researchfish
- The Francis Crick Institute [10169] Funding Source: researchfish
The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据